Details
Letrozol Indications
- Adjuvant therapy of hormone-positive breast cancer in early stages in postmenopausal women.
- Extended adjuvant early breast cancer treatment in postmenopausal women, who received standard adjuvant therapy with tamoxifen.
- Therapy of common forms of breast cancer in postmenopausal women as a first-line drug.
- Treatment of common forms of breast cancer in postmenopausal women in the event of progression of the disease after previous treatment with tamoxifen or other antiestrogens.
- Neo-adjuvant therapy in postmenopausal women with localized hormone-positive breast cancer, which provides an opportunity for further surgical treatment that surgery has not been shown before surgery. Further therapy after surgical treatment should be in accordance with the accepted standard for the postoperative period.
Contradictions
Hypersensitivity to the active substance or to any other component of the drug.
Endocrine status, characteristic for the premenopausal period.
Severe hepatic insufficiency (class C on Child's scale - Piu).
Preoperative use of the drug if the status of receptors is negative or unknown.
Dosage & Administration
2.5 mg once daily daily. In adjuvant therapy, treatment with Letrozol should last for 5 years or until relapse occurs.
